Dr Andrew Davidson

Dr Andrew Davidson

Senior Lecturer in Virology

School of Cellular and Molecular Medicine,
University of Bristol, Medical Sciences Building,
Bristol, BS8 1TD

phone: +44 (0)117 33 12024 (internal 12024)
email: andrew.davidson@bristol.ac.uk

group: Virology - dengue virus research group

Research interests

Research activities in the laboratory focus on investigating the replication and pathogenesis of Dengue virus and SARS coronavirus with an overall aim of developing improved antiviral agents and vaccines.

Dengue virus:

The dengue viruses are spread by mosquitoes and infect up to 50 million individuals annually in sub-tropical and tropical regions of the world. Dengue disease has emerged as the most important arthropod-borne viral disease of humans. Dengue virus infection generally results in dengue fever, a debilitating but self limited febrile disease. However, complications may arise, leading to the potentially fatal dengue haemorrhagic fever/dengue shock syndromes (DHF/DSS). Despite intensive research over recent years, the pathogenesis of DHF/DSS is still poorly understood and there is neither a safe and effective vaccine nor suitable anti-viral treatments to control dengue disease.

Current investigations in the laboratory focus on understanding the role of specific viral proteins in the virus lifecycle and the role they play in perturbing host cellular processes. Our studies use a dengue virus reverse genetic system, in combination with structural, biochemical and high throughput proteomic approaches to achieve these aims.

SARS coronavirus:

Severe acute respiratory syndrome (SARS) is a novel disease of humans that emerged in Southern China in late 2002 and rapidly spread worldwide causing ~ 8000 cases and 700 deaths. The etiological agent of SARS is a coronavirus which are enveloped, positive-strand RNA viruses that are commonly associated with enteric and respiratory diseases. Although the initial SARS epidemic was controlled by conventional measures, the animal reservoir for the SARSCoV progenitor has not been identified. It is therefore possible that SARS-CoV or a related virus could be reintroduced into the human population in the future. When this happens, the most economical and effective way to contain the virus will be the therapeutic use of an antiviral compound. In collaboration with Professor Siddell we are using a reverse genetic approach to understand the replication, pathogenesis and evolution of SARS-CoV.

Selected Publications

View all publications held on the University of Bristol's IRIS database

(Back to top)